Evolution of Psychoactive Substances Consumption in Connection With COVID-19 Containment (EPILOGUE)

Evolution of Psychoactive Substances Consumption in Connection With COVID-19 Containment - EPILOGUE

The current containment linked to COVID-19 will have consequences for people suffering from addiction and there is a risk of overdoses when the containment ends. So the investigators hypothesize that this health crisis is an opportunity to develop risk reduction and access to care for vulnerable people who lives with an addiction.

The main objective of this study is to describe the changes in the psychoactive substances consumption during the containment in people suffering from addiction. The secondary objectives are to describe the evolution at 1 month from the end of the containment of problematic consumption and the level of access to care of these users

Study Overview

• Status: Completed
• Conditions: COVID-19; Addiction, Substance

• Study Type: Observational
• Enrollment (Actual): 100

Contacts and Locations

Study Locations

• France
  • Montpellier, France, 34295
    • Uhmontpellier

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

• Sampling Method: Non-Probability Sample

Study Population

Person who lives with an addiction accepting the principle of the study

Description

Inclusion criteria:

• >18 years
• Accept study
• live with an addiction

Exclusion criteria:

- not being able to answer the questionnaire

Study Plan

How is the study designed?

Design Details

• Observational Models: Cohort
• Time Perspectives: Prospective

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Evolution of consumption	measurement of the difference in drugs consumption caused by containment (delta)	1 day
Evolution of consumption	measurement of the difference in drugs consumption caused by containment (delta)	1 month after confinmant

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
health care access	number of drug users referred to care (%)	1 day
health care access	number of drug users referred to care (%)	1 month after confinmant

Collaborators and Investigators

• Sponsor: University Hospital, Montpellier

Study record dates

Study Major Dates

• Study Start (Actual): April 8, 2020
• Primary Completion (Actual): July 30, 2020
• Study Completion (Actual): September 30, 2020

Study Registration Dates

• First Submitted: April 8, 2020
• First Submitted That Met QC Criteria: April 8, 2020
• First Posted (Actual): April 13, 2020

Study Record Updates

• Last Update Posted (Actual): October 8, 2020
• Last Update Submitted That Met QC Criteria: October 6, 2020
• Last Verified: April 1, 2020

More Information

Terms related to this study

• Keywords: Alcohol; Risk of overdose on de-confinment; COVID-19 containment will change drugs practices; COVID-19 containment will changes access to care; Addiction is a common disease; Containment; Drug use
• Additional Relevant MeSH Terms: Mental Disorders; Chemically-Induced Disorders; Coronavirus Infections; Coronaviridae Infections; Nidovirales Infections; RNA Virus Infections; Virus Diseases; Infections; Respiratory Tract Infections; Respiratory Tract Diseases; Pneumonia, Viral; Pneumonia; Lung Diseases; Compulsive Behavior; Impulsive Behavior; Substance-Related Disorders; COVID-19; Behavior, Addictive
• Other Study ID Numbers: RECHMPL20_0195

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: Undecided
• IPD Plan Description: NC

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No